Medifast Reports Q3 2026 Revenue of $72.05 Million, Sets Q4 Guidance
Revenue fell 19.4% year over year but exceeded analyst consensus of $71.3 million. Medifast reported a GAAP loss of $1.57 per share and set Q4 2026 revenue and GAAP EPS guidance midpoints of $65 million and $0.13. Full-year EBITDA guidance has a $12 million midpoint, above analyst consensus of $4.4 million.